主动靶向载药脂质体在肿瘤治疗中的研究进展  

Progresses on active targeting liposome drug delivery systems for tumor therapy

作　　者：张曼玉 楼晨曦(综述) 曹傲能(审校)[1] ZHANG Manyu;LOU Chenxi;CAO Aoneng(Institute of Nanochemistry and Nanobiology,Shanghai University,Shanghai 200444,P.R.China)

机构地区：[1]上海大学纳米化学与生物学研究所,上海200444

出　　处：《生物医学工程学杂志》2022年第3期633-638,共6页Journal of Biomedical Engineering

基　　金：国家自然科学基金资助项目(22071145,31871007);国家重点研发计划纳米专项课题(2016YFA0201602)。

摘　　要：脂质体是理想的药物载体,具有生物相容性好、无免疫原性、表面易功能化等众多优点,并已在肿瘤等疾病的临床治疗中得到应用。对于肿瘤治疗来说,脂质体本身虽然具有一定的被动靶向能力,但单一的被动靶向对提高药物在肿瘤组织的富集率的作用非常有限,主动靶向是提高药物富集率的有效措施。因此几十年来,主动靶向脂质体药物载体获得广泛研究。本文综述了基于载体与肿瘤细胞表面特异性结合的主动靶向脂质体药物载体的研究进展,并总结了该领域存在的机遇、挑战和未来前景。Liposome is an ideal drug carrier with many advantages such as excellent biocompatibility, nonimmunogenicity, and easy functionalization, and has been used for the clinical treatment of many diseases including tumors. For the treatment of tumors, liposome has some passive targeting capability, but the passive targeting effect alone is very limited in improving the drug enrichment in tumor tissues, and active targeting is an effective strategy to improve the drug enrichment. Therefore, active targeting liposome drug-carriers have been extensively studied for decades. In this paper, we review the research progresses on active targeting liposome drug-carriers based on the specific binding of the carriers to the surface of tumor cells, and summarize the opportunities, challenges and future prospects in this field.

关 键 词：脂质体 主动靶向 肿瘤治疗 

分 类 号：R73-36[医药卫生—肿瘤]